Proactiveinvestors recommends
Stocktube video
26/04/2013

ValiRx well-positioned to feed Big Pharma

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: VAL
1 year chart More charts
digital-look imported chart image
Deal VAL Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ValiRx
www.valirx.com
Deal ValiRx Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

ValiRx focus on the treatment of cancer, specialising in epigenomic and genetic analysis. Our technologies and products however can also be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and is...

Read more
Full ValiRx profile here
Pdf

ValiRx collaboration points the way to clinical trials

March 29 2012, 7:29am The work, which will be funded by the AIM-listed drug developer, is designed to prepare VAL201 for clinical trials.

 

ValiRx Plc (LON:VAL) has completed what it calls a material transfer agreement which will see the Institut Paoli & Calmettes in Marseille carry out translational and developmental studies on the company’s potential treatment for prostate cancer.

The work, which will be funded by the AIM-listed drug developer, is designed to prepare VAL201 for clinical trials.

Professor Jean-Paul Borg, scientific director of the IPC, will look in detail at the “molecular interaction and mimics of VAL201”.  

ValiRx chief executive Dr Satu Vainikka said: "I am very pleased that we have concluded this agreement with IPC and greatly look forward to working with Professor Borg and his team.  

“IPC is an internationally recognised centre of excellence for the study of cancer and it is one of our potential Phase One clinical centres. 

“This is another successful step along the way as VAL201 heads towards the clinic."

Late preclinical studies have marked the compound out as a potential breakthrough treatment for hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cell growth including breast and ovarian cancers.

VAL201 has already negotiated one regulatory hurdle, albeit a minor one, in that it complies with Good Manufacturing Practice.  

It is currently undergoing regulatory toxicology studies.


 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.